The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Inkeun Park
Consulting or Advisory Role - Amgen; Astellas Pharma Korea; BMS pharmaceutical Korea; Boryung Pharmaceuticals; Chong Kun Dang Pharmaceutical Co; daiichi sankyo korea; Janssen; Merck; Ono Pharmaceutical; Samsung Bioepis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Boryung Pharmaceutical Co (Inst); Chong Kun Dang Pharmaceutical Co. (Inst)
 
Shinkyo Yoon
Honoraria - MSD Oncology
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Boryung Pharmaceuticals; Daiichi Sankyo/Astra Zeneca
 
Sang Joon Shin
No Relationships to Disclose
 
Seong-Hoon Shin
No Relationships to Disclose
 
Jung Hoon Kim
No Relationships to Disclose
 
Kwonoh Park
No Relationships to Disclose
 
Jungmin Jo
No Relationships to Disclose
 
Hyo Jin Lee
No Relationships to Disclose
 
Jae Lyun Lee
Stock and Other Ownership Interests - Amgen; Johnson & Johnson/Janssen; Karyopharm Therapeutics; Merck; Zymeworks
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Merck; Novartis
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); Arcus Biosciences (Inst); AstraZeneca/MedImmune (Inst); Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); Eutilex (Inst); GI Innovation (Inst); Janssen (Inst); LG Chem (Inst); Loxo/Lilly (Inst); Merck KGaA (Inst); MSD (Inst); Novartis (Inst); Oscotec (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)